309 related articles for article (PubMed ID: 23415704)
1. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
[TBL] [Abstract][Full Text] [Related]
2. Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.
Hallett M; Albanese A; Dressler D; Segal KR; Simpson DM; Truong D; Jankovic J
Toxicon; 2013 Jun; 67():94-114. PubMed ID: 23380701
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of secretory disorders.
Naumann M; Dressler D; Hallett M; Jankovic J; Schiavo G; Segal KR; Truong D
Toxicon; 2013 Jun; 67():141-52. PubMed ID: 23178324
[TBL] [Abstract][Full Text] [Related]
4. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
[TBL] [Abstract][Full Text] [Related]
5. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
Naumann M; So Y; Argoff CE; Childers MK; Dykstra DD; Gronseth GS; Jabbari B; Kaufmann HC; Schurch B; Silberstein SD; Simpson DM;
Neurology; 2008 May; 70(19):1707-14. PubMed ID: 18458231
[TBL] [Abstract][Full Text] [Related]
6. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effects of detrusor botulinum toxin A injection on neurogenic detrusor overactivity in patients with different levels of spinal cord injury and types of detrusor sphincter dyssynergia.
Chen CY; Liao CH; Kuo HC
Spinal Cord; 2011 May; 49(5):659-64. PubMed ID: 21243000
[TBL] [Abstract][Full Text] [Related]
8. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.
Moore DC; Cohn JA; Dmochowski RR
Toxins (Basel); 2016 Mar; 8(4):88. PubMed ID: 27023601
[TBL] [Abstract][Full Text] [Related]
9. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.
Chung E
Expert Opin Biol Ther; 2015 Jan; 15(1):95-102. PubMed ID: 25347039
[TBL] [Abstract][Full Text] [Related]
10. Clinical differences between botulinum neurotoxin type A and B.
Bentivoglio AR; Del Grande A; Petracca M; Ialongo T; Ricciardi L
Toxicon; 2015 Dec; 107(Pt A):77-84. PubMed ID: 26260691
[TBL] [Abstract][Full Text] [Related]
11. Abo-, inco-, ona-, and rima-botulinum toxins in clinical therapy: a primer.
Chen JJ; Dashtipour K
Pharmacotherapy; 2013 Mar; 33(3):304-18. PubMed ID: 23400888
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of botulinum toxin A detrusor injections in the treatment of neurogenic detrusor overactivity after spinal cord injury.
Mehta S; Hill D; McIntyre A; Foley N; Hsieh J; Ethans K; Teasell RW; Loh E; Welk B; Wolfe D
Arch Phys Med Rehabil; 2013 Aug; 94(8):1473-81. PubMed ID: 23632286
[TBL] [Abstract][Full Text] [Related]
13. Contemporary management of lower urinary tract disease with botulinum toxin A: a systematic review of botox (onabotulinumtoxinA) and dysport (abobotulinumtoxinA).
Mangera A; Andersson KE; Apostolidis A; Chapple C; Dasgupta P; Giannantoni A; Gravas S; Madersbacher S
Eur Urol; 2011 Oct; 60(4):784-95. PubMed ID: 21782318
[TBL] [Abstract][Full Text] [Related]
14. Chapter 5: Clinical data in neurogenic detrusor overactivity (NDO) and overactive bladder (OAB).
Cruz F; Nitti V
Neurourol Urodyn; 2014 Jul; 33 Suppl 3():S26-31. PubMed ID: 25042140
[TBL] [Abstract][Full Text] [Related]
15. An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders.
Mangera A; Apostolidis A; Andersson KE; Dasgupta P; Giannantoni A; Roehrborn C; Novara G; Chapple C
Eur Urol; 2014 May; 65(5):981-90. PubMed ID: 24239446
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
[TBL] [Abstract][Full Text] [Related]
17. Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report.
Apostolidis A; Dasgupta P; Denys P; Elneil S; Fowler CJ; Giannantoni A; Karsenty G; Schulte-Baukloh H; Schurch B; Wyndaele JJ;
Eur Urol; 2009 Jan; 55(1):100-19. PubMed ID: 18823697
[TBL] [Abstract][Full Text] [Related]
18. Use of botulinum toxin in individuals with neurogenic detrusor overactivity: state of the art review.
Linsenmeyer TA
J Spinal Cord Med; 2013 Sep; 36(5):402-19. PubMed ID: 23941788
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy for overactive bladder: minimally invasive treatment -- botulinum toxins.
Apostolidis A
Expert Opin Pharmacother; 2011 May; 12(7):1029-39. PubMed ID: 21288184
[TBL] [Abstract][Full Text] [Related]
20. Hyperhidrosis: anatomy, pathophysiology and treatment with emphasis on the role of botulinum toxins.
Lakraj AA; Moghimi N; Jabbari B
Toxins (Basel); 2013 Apr; 5(4):821-40. PubMed ID: 23612753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
